MedImmune’s Motavizumab Reduced RSV Hospitalizations By 83 Percent Among Native American, Full-Term Infants In Placebo-Controlled Phase 3 Study
MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p [click link for full article]
(more...)
(more...)
